Register update: there will be a delay adding new records during our holiday period (Dec 17 - Jan 4)
Cochrane COVID-19 Study Register
Study record
NCT04747574First Published: 2021 Feb 11Updated Date: 2021 Feb 11

A Phase I Feasibility Study to Evaluate the Safety of CD24-Exosomes in Patients With Moderate/Severe COVID-19 Infection

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Single Arm/Controlled Before After
  1. Intervention Assignment
  2. Not Applicable
Reference record

Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

NCT04747574
Trial registry record
No Results
This is an open-label Phase I study, three dose escalation groups, to evaluate the safety of CD24-exosomes in patients with moderate/severe COVID-19 disease. Patients with moderate/severe COVID-19 infection and factors predictive of a cytokine storm are recruited from the Corona department of the Tel Aviv Sourasky Medical Center (TASMC), who have provided informed consent are being recruited in three dose groups who will receive the exosome treatment as an add-on treatment to standard treatment